130 related articles for article (PubMed ID: 2904995)
1. The effect of ciprofibrate on gastric secretion in the rat.
Eason CT; Pattison A; Howells DD; Bonner FW
J Pharm Pharmacol; 1988 Jul; 40(7):512-3. PubMed ID: 2904995
[TBL] [Abstract][Full Text] [Related]
2. Assessment of gastric antisecretory effects of phenoxyisobutyrate derivatives in the rat and the mouse.
Eason CT; Pattison A; Howells DD; Spencer AJ; Bonner FW
Scand J Gastroenterol; 1988 Nov; 23(9):1063-71. PubMed ID: 3247588
[TBL] [Abstract][Full Text] [Related]
3. Gastric morphological changes including carcinoid tumors in animals treated with a potent hypolipidemic agent, ciprofibrate.
Spencer AJ; Barbolt TA; Henry DC; Eason CT; Sauerschell RJ; Bonner FW
Toxicol Pathol; 1989; 17(1 Pt 1):7-15. PubMed ID: 2501865
[TBL] [Abstract][Full Text] [Related]
4. The effect of the peroxisome proliferator ciprofibrate on the gastric mucosa and particularly the gastrin cell.
Waldum HL; Kvetnoi IM; Sylte R; Schulze B; Martinsen TC; Sandvik AK
J Mol Endocrinol; 1998 Feb; 20(1):111-7. PubMed ID: 9513087
[TBL] [Abstract][Full Text] [Related]
5. Metabolic effects of a new hypolipidemic agent, ciprofibrate.
Arnold A; McAuliff MP; Beyler AL
J Pharm Sci; 1979 Dec; 68(12):1557-8. PubMed ID: 529054
[TBL] [Abstract][Full Text] [Related]
6. Comparative hypolipidaemic and peroxisomal effects of ciprofibrate, clofibric acid, and their respective difluorocyclopropyl and 4-fluoro-substituted analogues in rat.
Graham MJ; Winham MA; Old SL; Gray TJ
Xenobiotica; 1996 Jul; 26(7):695-707. PubMed ID: 8819300
[TBL] [Abstract][Full Text] [Related]
7. Potentiating hypergastrinemic effect by the peroxisome proliferator ciprofibrate and omeprazole in the rat.
Hammer TA; Sandvik AK; Waldum HL
Scand J Gastroenterol; 1998 Jun; 33(6):595-9. PubMed ID: 9669630
[TBL] [Abstract][Full Text] [Related]
8. Characterization of ciprofibrate and clofibric acid as peroxisomal proliferators in primary cultures of rat hepatocytes.
Feller DR; Singh Y; Shirhatti VR; Kocarek TA; Liu CT; Krishna G
Hepatology; 1987; 7(3):508-16. PubMed ID: 3570161
[TBL] [Abstract][Full Text] [Related]
9. Irreversible inhibition of hepatic glutathione S-transferase by ciprofibrate, a peroxisome proliferator.
Awasthi YC; Singh SV; Goel SK; Reddy JK
Biochem Biophys Res Commun; 1984 Sep; 123(3):1012-8. PubMed ID: 6487318
[TBL] [Abstract][Full Text] [Related]
10. Species variation in gastric toxicity following chronic administration of ciprofibrate to rat, mouse, and marmoset.
Eason CT; Spencer AJ; Pattison A; Howells DD; Henry DC; Bonner FW
Toxicol Appl Pharmacol; 1988 Sep; 95(2):328-38. PubMed ID: 3138789
[TBL] [Abstract][Full Text] [Related]
11. Effect of the peroxisome proliferator ciprofibrate on hepatic DNA synthesis and hepatic composition following partial hepatectomy in rats.
Srinivasan SR; Chow CK; Glauert HP
Toxicology; 1990 Jun; 62(3):321-32. PubMed ID: 2389247
[TBL] [Abstract][Full Text] [Related]
12. Effects of ciprofibrate and 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylate (POCA) on the distribution of carnitine and CoA and their acyl-esters and on enzyme activities in rats. Relation between hepatic carnitine concentration and carnitine acetyltransferase activity.
Bhuiyan AK; Bartlett K; Sherratt HS; Agius L
Biochem J; 1988 Jul; 253(2):337-43. PubMed ID: 3178716
[TBL] [Abstract][Full Text] [Related]
13. An in vitro demonstration of peroxisome proliferation and increase in peroxisomal beta-oxidation system mRNAs in cultured rat hepatocytes treated with ciprofibrate.
Thangada S; Alvares K; Mangino M; Usman MI; Rao MS; Reddy JK
FEBS Lett; 1989 Jul; 250(2):205-10. PubMed ID: 2753129
[TBL] [Abstract][Full Text] [Related]
14. Induction and origin of hepatocytes in rat pancreas.
Reddy JK; Rao MS; Qureshi SA; Reddy MK; Scarpelli DG; Lalwani ND
J Cell Biol; 1984 Jun; 98(6):2082-90. PubMed ID: 6202703
[TBL] [Abstract][Full Text] [Related]
15. [The pharmacokinetics of antilipemic agents. 5. Is 2-(4-hydroxyphenoxy)-2-methylpropionic acid a metabolite of the antilipemic ciprofibrate?].
Oelschläger H; Rothley D; Hellwich KH; Schmidt W
Arch Pharm (Weinheim); 1989 Jun; 322(6):337-42. PubMed ID: 2774869
[TBL] [Abstract][Full Text] [Related]
16. [The pharmacokinetics of hypolipemic agents. 6. Is 2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-propane a metabolite of the hypolipemic ciprofibrate?].
Oelschläger H; Rothley D; Hellwich KH; Schmidt W
Arch Pharm (Weinheim); 1989 Oct; 322(10):629-32. PubMed ID: 2624522
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the hepatic responses to the short-term administration of ciprofibrate in several rat strain. Co-induction of microsomal cytochrome P-450 IVA1 and peroxisome proliferation.
Makowska JM; Anders C; Goldfarb PS; Bonner F; Gibson GG
Biochem Pharmacol; 1990 Sep; 40(5):1083-93. PubMed ID: 2390105
[TBL] [Abstract][Full Text] [Related]
18. The peroxisome-proliferator ciprofibrate induces hypergastrinemia without raising gastric pH.
Martinsen TC; Nesjan N; Rønning K; Sandvik AK; Waldum HL
Carcinogenesis; 1996 Oct; 17(10):2153-5. PubMed ID: 8895482
[TBL] [Abstract][Full Text] [Related]
19. Influence of a fibric acid type of hypolipidemic agent on the oxidative metabolism of arachidonic acid by liver microsomal cytochrome P-450.
Capdevila J; Kim YR; Martin-Wixtrom C; Falck JR; Manna S; Estabrook RW
Arch Biochem Biophys; 1985 Nov; 243(1):8-19. PubMed ID: 3933431
[TBL] [Abstract][Full Text] [Related]
20. Effect of ciprofibrate, bezafibrate, and LY171883 on peroxisomal beta-oxidation in cultured rat, dog, and rhesus monkey hepatocytes.
Foxworthy PS; White SL; Hoover DM; Eacho PI
Toxicol Appl Pharmacol; 1990 Jul; 104(3):386-94. PubMed ID: 1974728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
